Preliminary results of a Phase I/II study with pi-meson (pion) treatment for bladder cancer.
Radiation therapy with negative pi-mesons (pions) was administered to 36 patients with bladder cancer. According to a Phase I/II study, doses varied from 3000 to 3600 pion rad. Although only two complete responses were achieved among 8 evaluable patients who had predominantly papillary bladder tumors, more promising results were obtained in 22 evaluable patients who had sessile, invasive carcinomas: 19 bladders were cystoscopically and cytologically cleared of tumor after 6 months. Although the side effects during the ambulatory treatment were minimal or tolerable, a steep dose-response curve for late side effects was observed with severe complications in 7 of 11 patients who received 3600 or more pion rad.
D000230:Adenocarcinoma / Q000401:mortality / Q000532:radiotherapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000401:mortality / Q000532:radiotherapy; D002278:Carcinoma in Situ / Q000401:mortality / Q000532:radiotherapy; D002296:Carcinosarcoma / Q000401:mortality / Q000532:radiotherapy; D004601:Elementary Particles; D005069:Evaluation Studies as Topic; D005260:Female; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D008297:Male; D008651:Mesons; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D011879:Radiotherapy Dosage; D011882:Radiotherapy, High-Energy / Q000009:adverse effects / Q000379:methods*; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000532:radiotherapy*